What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?Zacks Investment Research • 09/09/25
Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 08/07/25
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue GuidanceBusiness Wire • 08/07/25
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025Business Wire • 07/31/25
Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term InvestingSeeking Alpha • 06/18/25
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor DayBusiness Wire • 06/03/25
Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025Business Wire • 05/01/25
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?Zacks Investment Research • 03/20/25
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic AidBusiness Wire • 03/17/25
Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 EarningsZacks Investment Research • 03/06/25
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 GuidanceBusiness Wire • 03/06/25